Quinupristin–dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: Efficacy and development of resistance

References

• Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988;319:157–61.
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470–85.
   PubMed Web of Science ®Google Scholar
• Montecalvo MA, Shay DK, Patel P, Tacsa L, Maloney SA, Jarvis WR, . Bloodstream infections with vancomycin-resistant enterococci. Arch Intern Med 1996;156:1458–62.
   PubMedGoogle Scholar
• Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group. J Antimicrob Chemother 1999;44:251–61.
   PubMed Web of Science ®Google Scholar
• Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002;62:425–41.
   PubMed Web of Science ®Google Scholar
• Linden PK, Moellering RC Jr, Wood CA, Rehm SJ, Flaherty J, Bompart F, . Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin. Clin Infect Dis 2001;33:1816–23.
   PubMed Web of Science ®Google Scholar
• Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. Clin Infect Dis 2003;36:159–68.
   PubMed Web of Science ®Google Scholar
• Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin–dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis 2008;46:30–6.
   PubMed Web of Science ®Google Scholar
• Raad I, Hachem R, Hanna H, Afif C, Escalante C, Kantarjian H, . Prospective, randomized study comparing quinupristin–dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. J Antimicrob Chemother 2004;53:646–9.
   PubMed Web of Science ®Google Scholar
• Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother 2008;52:2256–9.
   PubMed Web of Science ®Google Scholar
• Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin Infect Dis 2002;35:1269–72.
   PubMed Web of Science ®Google Scholar
• Hershberger E, Donabedian S, Konstantinou K, Zervos MJ. Quinupristin–dalfopristin resistance in Gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 2004;38:92–8.
   PubMed Web of Science ®Google Scholar
• Oh WS, Ko KS, Song JH, Lee MY, Park S, Peck KR, . High rate of resistance to quinupristin–dalfopristin in Enterococcus faecium clinical isolates from Korea. Antimicrob Agents Chemother 2005;49:5176–8.
   PubMed Web of Science ®Google Scholar
• Noskin GA, Till M, Patterson BK, Clarke JT, Warren JR. High-level gentamicin resistance in Enterococcus faecalis bacteremia. J Infect Dis 1991;164:1212–5.
   PubMed Web of Science ®Google Scholar
• Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, . Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001;32: 1249–72.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical and Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M100-S12. Wayne, PA: NCCLS; 2002.
   Google Scholar
• National Committee for Clinical and Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Eighth ed. Approved standard M2-A8. Wayne, PA: NCCLS; 2002.
   Google Scholar
• Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996;23:1234–9.
   PubMed Web of Science ®Google Scholar
• Lautenbach E, Schuster MG, Bilker WB, Brennan PJ. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus. Clin Infect Dis 1998;27:1259–65.
   PubMed Web of Science ®Google Scholar
• Linden PK, Pasculle AW, McDevitt D, Kramer DJ. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997;39(Suppl A):145–51.
   PubMedGoogle Scholar
• Dowzicky M, Talbot GH, Feger C, Prokocimer P, Etienne J, Leclercq R. Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid) during a worldwide clinical program. Diagn Microbiol Infect Dis 2000;37:57–62.
   PubMed Web of Science ®Google Scholar
• Weisblum B. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression—a review. J Antimicrob Chemother 1985;16(Suppl A):63–90.
   PubMedGoogle Scholar
• Bozdogan B, Leclercq R. Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin–dalfopristin against Enterococcus faecium. Antimicrob Agents Chemother 1999;43:2720–5.
   PubMed Web of Science ®Google Scholar
• Schmitz FJ, Sadurski R, Kray A, Boos M, Geisel R, Kohrer K, . Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother 2000;45:891–4.
   PubMed Web of Science ®Google Scholar
• Lopez F, Culebras E, Betriu C, Rodriguez-Avial I, Gomez M, Picazo JJ. Antimicrobial susceptibility and macrolide resistance genes in Enterococcus faecium with reduced susceptibility to quinupristin–dalfopristin: level of quinupristin–dalfopristin resistance is not dependent on erm(B) attenuator region sequence. Diagn Microbiol Infect Dis 2010;66:73–7.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Siempos, II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008;8:53–66.
   PubMed Web of Science ®Google Scholar
• Hachem RY, Hicks K, Huen A, Raad I. Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients. Clin Infect Dis 2003;37:e8–11.
   PubMed Web of Science ®Google Scholar